Drugs / PD-1/IL-2 Bispecific Antibody Fusion Protein
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07644208 | Jun 2026 → Jun 2028 expected | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD-1/IL-2 Bispecific Antibody Fusion Protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07644208 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT07644208 ↗ |